Agios Pharmaceuticals Inc (USD)
AGIO
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range39.93 | 40.95
52-Wk Range28.36 | 68.94
Last Close40.08
Mkt Cap (m)2,740.29
Dividend yield-
ISINUS00847X1046
Volume426,027
Exchange VenueNAS

Company Profile

Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.

Key Information
Price/Earning-
Price/Book6.11
Price/Sales20.86
P/CF-
Rev Growth (3 year avg)16.88
EPS Growth (3 year avg)-
Operating Margin % -384.03
Net Margin %-366.61
Return on Equity-65.10
Debt/Equity-

Legal Documents

Prospectus
en 08/11/2019
Annual Report
en 31/12/2018

Financials

Income Statement
USD201320142015201620172018
Revenue (m)266559704394
Operating Income (m)-39-54-119-201-321-362
Net Income (m)-39-54-118-198-315-346
Basic EPS-2.83-1.59-3.15-5.07-6.75-6.03
Avg. Diluted Shares Outstanding (m)153437394757
Balance Sheet
USD201320142015201620172018
Current Assets (m)170360337560445614
Non Current Assets (m)311328359169245
Total Assets (m)201492420619614858
Current Liabilities (m)376153889594
Total Liabilities (m)------
Total Equity (m)131424345359376688
Cash Flows
USD201320142015201620172018
Operating Cash Flows (m)-56-59-7739-285-304
Capital Expenditure (m)-1-2-20-10-5-7
Figures are quoted in USD unless stated otherwise
0.57 (1.42%)
$
40.65
Last Price